Oral-AZA
5 abstracts
Abstract
A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.Org: Ludwig Boltzmann Institute for Hematology and Oncology,
Abstract
Real-world (RW) antiemetic use and its association with duration of oral azacitidine (Oral-AZA) maintenance in patients (pts) with acute myeloid leukemia (AML) in the United States (US).Org: STATinMED Research,
Abstract
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.Org: Marien Hospital Düsseldorf, Cancer Center IRCCS Humanitas Research Hospital, IRCSS Azienda Ospedaliera Universitaria di Bologna, MDS Unit, Service d'Hématologie Séniors,
Abstract
A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).Org: MD Anderson Cancer Center, MDS Unit, Bristol Myers Squibb, Sylvester Comprehensive Cancer Center, Miami, FL, Marien Hospital Düsseldorf,
Abstract
Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.Org: Bristol Myers Squibb, MD Anderson Cancer Center,